X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (50) 50
index medicus (40) 40
immunotherapy (30) 30
oncology (27) 27
female (25) 25
cancer (24) 24
male (24) 24
aged (21) 21
middle aged (21) 21
adult (18) 18
melanoma (18) 18
ipilimumab (17) 17
immunology (15) 15
antibodies, monoclonal - therapeutic use (14) 14
cell biology (13) 13
care and treatment (12) 12
metastatic melanoma (12) 12
antineoplastic agents - therapeutic use (11) 11
melanoma - drug therapy (11) 11
cancer research (10) 10
mesothelioma (10) 10
monoclonal antibodies (10) 10
chemotherapy (9) 9
expression (9) 9
medicine & public health (9) 9
metastasis (9) 9
open-label (9) 9
research (9) 9
treatment outcome (9) 9
aged, 80 and over (8) 8
antigens (8) 8
lung neoplasms - drug therapy (8) 8
melanoma - pathology (8) 8
physiology (8) 8
survival (8) 8
tumors (8) 8
young adult (8) 8
antibodies, monoclonal - administration & dosage (7) 7
antibodies, monoclonal - adverse effects (7) 7
clinical trials (7) 7
mesothelioma - drug therapy (7) 7
patients (7) 7
pleural mesothelioma (7) 7
prognosis (7) 7
therapy (7) 7
tremelimumab (7) 7
analysis (6) 6
animals (6) 6
combination (6) 6
drug therapy (6) 6
hematology, oncology and palliative medicine (6) 6
italy (6) 6
medical research (6) 6
melanoma - immunology (6) 6
neoplasm metastasis (6) 6
neoplasm staging (6) 6
neurosciences (6) 6
phase-ii (6) 6
rehabilitation (6) 6
respiratory system (6) 6
single-arm (6) 6
adolescent (5) 5
antibodies (5) 5
ctla-4 (5) 5
ctla-4 antigen - immunology (5) 5
double-blind (5) 5
immunotherapy - methods (5) 5
lymphocytes (5) 5
medicine (5) 5
neoplasms - immunology (5) 5
neoplasms - therapy (5) 5
safety (5) 5
solid tumors (5) 5
stroke (5) 5
trial (5) 5
up-regulation (5) 5
usage (5) 5
antibodies, monoclonal - pharmacology (4) 4
cancer-immunotherapy (4) 4
cell line, tumor (4) 4
cells (4) 4
connectivity (4) 4
cortex (4) 4
ctla-4 antigen - antagonists & inhibitors (4) 4
dacarbazine (4) 4
eeg (4) 4
expanded access programme (4) 4
follow-up studies (4) 4
gene expression regulation, neoplastic (4) 4
lung cancer (4) 4
lung neoplasms - pathology (4) 4
medicine, experimental (4) 4
melanoma - mortality (4) 4
metastases (4) 4
modulation (4) 4
networks (4) 4
oncology, experimental (4) 4
plasticity (4) 4
skin neoplasms - drug therapy (4) 4
skin neoplasms - pathology (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 6/2013, Volume 62, Issue 6, pp. 1021 - 1028
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 8/2009, Volume 58, Issue 8, pp. 1297 - 1306
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 1/2012, Volume 61, Issue 1, pp. 41 - 48
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2018, Volume 19, Issue 11, pp. 1468 - 1479
Journal Article
Cell Research, ISSN 1001-0602, 02/2015, Volume 25, Issue 2, pp. 208 - 224
The cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antibody ipilimumab induces immune-mediated long-term control of metastatic melanoma in a fraction of... 
sCD25 | tumor immunotherapy | ipilimumab | IL-2 | cancer | CTLA-4 blockade | Original | CD122
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 4/2011, Volume 60, Issue 4, pp. 467 - 477
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 8/2018, Volume 67, Issue 8, pp. 1317 - 1324
Treatment of malignant pleural mesothelioma (MPM) represents a highly unmet medical need. Here, we discuss the results and therapeutic potential of first- and... 
Immunology | Immune checkpoint | Medicine & Public Health | Immunotherapy | Oncology | Cancer Research | Mesothelioma | NIBIT-2016 | RESPONSE CRITERIA | PHASE-III | TREMELIMUMAB | GUIDELINES | MALIGNANT PLEURAL MESOTHELIOMA | OPEN-LABEL | IMMUNOLOGY | SINGLE-ARM | TRIAL | ONCOLOGY | DOUBLE-BLIND | T-CELLS | Viral antibodies | Antibodies | Immunomodulation
Journal Article
Journal Article
Journal Article